LAVAL, QUEBEC: Valeant Pharmaceuticals has brought on Scott Hirsch as SVP of business strategy and communications.
Longtime PR and investor relations leader Laurie Little is also planning to depart the company, it said on Monday.
Little, who has led the pharmaceutical company’s IR and PR for the past nine years, will exit the drugmaker "in the coming months," it said in a statement.
Hirsch previously worked at Citadel Investment Group, where he was a portfolio manager within the healthcare sector. Previously, he was the lead equity research analyst for specialty pharmaceuticals and global generics for Credit Suisse He also has five years of experience in venture capital operating roles at JP Morgan and Morgan Stanley.
Shares of Valeant have lost nine-tenths of their value since last August, due to issues from accounting problems to investigations by federal lawmakers and regulators.
In March, CEO Michael Pearson stepped down; he was replaced by Joseph Papa the following month.
A Valeant representative could not be immediately reached for comment.